title: Chronic kidney disease: Statins in chronic kidney disease: time to move on?
abstract: Statins reduce the risk of atherosclerotic vascular disease in healthy individuals and those with chronic kidney disease (CKD); however, clinical trials have suggested a minimal effect of statins on CKD progression. The PLANET trials compared the renal effects of rosuvastatin and atorvastatin, but the findings leave many questions unanswered.
authors: Clinical Trial Service Unit &Epidemiological Studies Unit, Richard Doll Building, Old Road Campus, Headington, Oxford OX3 7LF, UK.
authors: Richard
authors: R
authors: Haynes
authors: Renal Division, University Hospital of Würzburg, Oberdürrbacherstrasse 6, 97080 Würzburg, Germany.
authors: Christoph
authors: C
authors: Wanner
mesh_terms: D048909:Diabetes Complications / Q000188:drug therapy*; D003928:Diabetic Nephropathies / Q000188:drug therapy*; D005464:Fluorobenzenes / Q000627:therapeutic use*; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D007668:Kidney / Q000187:drug effects*; D011743:Pyrimidines / Q000627:therapeutic use*; D011758:Pyrroles / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*
chemical_list: D005464:Fluorobenzenes; D006538:Heptanoic Acids; D011743:Pyrimidines; D011758:Pyrroles; D013449:Sulfonamides